MedPath

Occipital Nerve Stimulation for the Treatment of Chronic Migraine Headache.

Phase 1
Completed
Conditions
Chronic Migraine Headache
Interventions
Device: Occipital Nerve Stimulation
Registration Number
NCT00200109
Lead Sponsor
MedtronicNeuro
Brief Summary

Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache greater than 15 days per month.

Method: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responsers were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups.

Detailed Description

The therapy under investigation involves a Medtronic neurostimulation device which delivers electrical impulses via insulated lead wires placed under the skin near the occipital nerves at the base of the head.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
110
Inclusion Criteria
  • Diagnosis of Chronic Migraine Headache by International Headache Society (IHS) criteria
  • compliance with daily questionnaire
  • headache that has not responded to at least two classes of headache medications
  • stable headache medication regimen
Exclusion Criteria
  • previous surgical procedures to disrupt the nerves of the neck relating to the headache
  • subjects who may require MRI or Diathermy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 2Occipital Nerve StimulationSee protocol
Group 3Occipital Nerve StimulationSee protocol
Group 1Occipital Nerve StimulationSee protocol
Group 4Occipital Nerve StimulationSee protocol
Primary Outcome Measures
NameTimeMethod
A primary endpoint is not identified for this feasibility study.No primary endpoint
Secondary Outcome Measures
NameTimeMethod
Secondary endpoints included: patient daily questionnaire, Migraine Disability Assessment (MIDAS), functional disability, SF-36, acute medication use and subject satisfaction surveys.No secondary endpoint

Trial Locations

Locations (2)

Contact Medtronic for Exact Location

πŸ‡¬πŸ‡§

London, United Kingdom

Contact Medtronic for Exact Locations

πŸ‡ΊπŸ‡Έ

Philadelphia, Pennsylvania, United States

Β© Copyright 2025. All Rights Reserved by MedPath